AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06666660 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will be given 180 placebo tablets in bottles at baseline visit, and another 180 tablets at 6-month visit. Participants will be advised to take 1 tablet orally, daily, in the morning before food. Participants will be asked to return the remainder of dispensed placebo tablets, along with the bottle when they come for visit 2 and visit 3. This is done for investigational product accounting and checking for adherence to the assigned treatment arm. The placebo pills and bottles will be identical in appearance as MVM to ensure effective blinding.
Study NCT04871100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol- Alcohol
Description: Transdiagnostic cognitive behavior therapy for emotional disorders modified to include CBT for alcohol use.
Study NCT04871100 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: referrals to VA care for SUD and anxiety
Study NCT05868915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HV-101
Description: Biological: HV-101~HV-101 is autologous tumor-infiltrating lymphocyte cells without genetic modification.~Drug: IL-2~Following cell infusion, the patient receives intravenous IL-2.~Drug: Fludarabine~Part of the non-myeloablative lymphocyte-depleting preparative regimen.~Drug: Cyclophosphamide~Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Study NCT05049798 — intervention group
Intervention type: DRUG
Intervention: Guselkumab
Description: Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with guselkumab, will be observed according to standard clinical practice.
Study NCT05049798 — intervention group
Intervention type: DRUG
Intervention: IL-17i
Description: Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with IL-17i, will be observed according to standard clinical practice.
Study NCT06273111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% simvastatin ointment
Description: 5% simvastatin ointment will be applied directly on IH lesion twice per day for 24 weeks
Study NCT04187040 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Study intervention: 3-step hand hygiene technique
Description: 3-step hand hygiene technique:~1. Covering all surfaces of the hands (based on own judgement)~2. Rotational rubbing of fingertips in the palm of the alternate hand~3. Rotational rubbing of both thumbs
Study NCT04187040 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention: 6-step hand hygiene technique
Description: 6-step hand hygiene technique (according to the WHO Guidelines on Hand Hygiene in Health Care, First Global Patient Safety Challenge):~1. Rubbing hands palm to palm~2. Palm to palm with fingers interlaced~3. Right palm over left dorsum with interlaced fingers and vice versa~4. Back of fingers to opposing palms with fingers interlocked~5. Rotational rubbing of left thumb clasped in right palm and vice versa~6. Rotational rubbing backwards and forwards with clasped fingers of right hand in left palm and vice versa
Study NCT06348836 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Description of exercises are noted in the arms/groups descriptions
Study NCT06209788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: experimental group
Description: The music intervention consists of two parts. The first part occurs during the surgical procedure, starting from the induction of anesthesia and continuing until the surgery over. The second part spans from the first day post-surgery to the fifth day (or until discharge), with the patient listening to music twice a day, each session lasting for 30 minutes. The planned times for the music sessions are expected to be at 11 a.m. and 8 p.m. Each day post-surgery, the music intervention must be completed, and measurements of respiratory rate, pulse rate, blood pressure, and pain score should be taken both before and after listening to the music. Other are routine post-operative care.
Study NCT06665230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6552
Description: Oral administration
Study NCT06665230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Oral administration
Study NCT06668857 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: video-oculography
Description: All participants will receive quantitative oculomotor and pupillomotor measurements using two different video-oculography devices. Thereby both pursuit eye movements, saccades and pupillary responses to light will be assessed. In addition, there will be a quantitative assessment of the angular vestibulo-ocular reflex (aVOR) by use of video-head-impulse testing and a hearing test.
Study NCT06588751 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scalp block
Description: After the surgical procedure, patients in Group S were placed in a semi-sitting position. Following skin antisepsis with 5% povidone-iodine, a sterile drape was applied. A circumferential scalp block with 2 cc of 0.25% bupivacaine was done on each of the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, greater occipital, and lesser occipital nerves that supply the forehead and scalp with sensory information. The procedure was performed bilaterally. The supratrochlear and supraorbital nerves were blocked at the brow, close to the upper middle edge orbit, and over the supraorbital notch that could be felt. The zygomaticotemporal nerve was blocked between the posterior edge of the zygomatic arch. The auriculotemporal nerve was blocked at the level of the tragus. The greater and lesser occipital nerves were blocked at the medial and lateral thirds of the superior nuchal line.
Study NCT06588751 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Scalp block
Description: After the surgical procedure, patients in Group S were placed in a semi-sitting position. Following skin antisepsis with 5% povidone-iodine, a sterile drape was applied. A circumferential scalp block with 2 cc of 0.25% bupivacaine was done on each of the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, greater occipital, and lesser occipital nerves that supply the forehead and scalp with sensory information. The procedure was performed bilaterally. The supratrochlear and supraorbital nerves were blocked at the brow, close to the upper middle edge orbit, and over the supraorbital notch that could be felt. The zygomaticotemporal nerve was blocked between the posterior edge of the zygomatic arch. The auriculotemporal nerve was blocked at the level of the tragus. The greater and lesser occipital nerves were blocked at the medial and lateral thirds of the superior nuchal line.
Study NCT06665373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Atkins Diet
Description: The Atkins diet is a low-carb eating plan that focuses on balancing protein, fat, and carbohydrates.
Study NCT06665373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitness Program
Description: 12 weeks of two weekly supervised exercise sessions combined with an individualized home exercise program based on physical capabilities and available equipment.
Study NCT06665061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCV
Description: Patients were randomly assigned to receive PCV mechanical ventilation, with consistent ventilation parameters.
Study NCT06665061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VCV
Description: Patients were randomly assigned to receive VCV mode mechanical ventilation, with consistent ventilation parameters.
Study NCT06665061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRVC
Description: Patients were randomly assigned to receive PRVC mode mechanical ventilation, with consistent ventilation parameters.
Study NCT06667739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPACT-L3
Description: The intervention is a physical activity behaviour change intervention: IMproving Physical Activity through Coaching and Technology following Lower Limb Loss (IMPACT-L3). Two theories provide a framework for IMPACT-L3. One is social cognitive theory and the other is self-determination theory. As mHealth solutions have the potential to increase access and improve health outcomes, IMPACT-L3 will be delivered entirely virtually.
Study NCT04218331 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: JASPER
Description: JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the clinician/therapist.
Study NCT04218331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JASPER
Description: JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the clinician/therapist.
Study NCT04218331 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROMPT
Description: PROMPT is a multidimensional oral-motor approach to speech production disorders.
Study NCT06666530 — intervention group
Intervention type: OTHER
Intervention: Questionary
Description: Three self-questionnaires, either completed independently or with assistance, will be administered at inclusion (between the first obstetric ultrasound and 28 weeks of amenorrhea), during the third trimester of pregnancy, and at 1 year postpartum
Study NCT06666309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBCM-PrEP + Text Messaging
Description: Two sessions Strengths-Based Case Management intervention adapted for HIV PrEP related educational content delivered to individual clients in the syringe service program setting
Study NCT05016349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All trans-retinoic acid
Description: Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
Study NCT05016349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-Cis Retinoic Acid plus Tocopherol
Description: 13-Cis Retinoic Acid (50 mg/m2/d) Tocopherol (800 mg/day) supplied orally at the total dosage of 50 mg/m2/d (two daily administrations of 25 mg/m2 each). Treatment will last 28 days
Study NCT05016349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 200mg capsules daily for 28 days
Study NCT06666309 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CDC-PrEP + Text Messaging
Description: 1 session PrEP education based on CDC guidelines delivered to individual clients in syringe service program settings
Study NCT06666309 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CDC-PrEP + Text Messaging
Description: 1 session PrEP education based on CDC guidelines delivered to individual clients in syringe service program settings
Study NCT06666309 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: T-SBCM
Description: Up to two post-linkage sessions of SBCM delivered by a peer support specialist in a format of the participants' choice (onsite, virtual/phone) in study month 2
Study NCT06666309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T-SBCM
Description: Up to two post-linkage sessions of SBCM delivered by a peer support specialist in a format of the participants' choice (onsite, virtual/phone) in study month 2
Study NCT06666309 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mobile Outreach
Description: Up to two in-person field session visits will be conducted by a peer support specialist for the purpose of offering direct support to arrange joint activities for overcoming identified barriers (e.g., transportation) to PrEP care initiation in study month 2.
Study NCT06666309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Outreach
Description: Up to two in-person field session visits will be conducted by a peer support specialist for the purpose of offering direct support to arrange joint activities for overcoming identified barriers (e.g., transportation) to PrEP care initiation in study month 2.
Study NCT06665711 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3% Hypertonic Saline
Description: In this arm of the study, participants will receive nebulized 3% hypertonic saline as the primary treatment for bronchiolitis. The administration of hypertonic saline is aimed at reducing airway edema and improving mucociliary clearance in infants experiencing respiratory distress due to bronchiolitis.
Study NCT06665711 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention: Salbutamol (Ventolin)
Description: In this arm of the study, participants will receive nebulized Salbutamol, a bronchodilator commonly used in the management of bronchospasm associated with respiratory conditions, including bronchiolitis. The objective is to evaluate the effectiveness of Salbutamol in comparison to 3% hypertonic saline in improving the clinical outcomes of infants with bronchiolitis.
Study NCT06670508 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominis Plane block
Description: Group A, The patient was in the supine position then; the TAP block was given by a high frequency linear ultrasound transducer (Siemens acuson x300 3-5MHz ultrasound). After skin preparation and isolation, the transducer was placed 2 cm sub-xiphoid, then moved along the subcostal edge to identify the rectus abdominis muscle and the transversus abdominis then, a blunted tip, 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) was introduced in-plane 2-3 cm lateral to the transducer, under direct ultrasound visualization. After confirming the correct placement of the needle and the negative aspiration probe, the rest of the anaesthetic substance was injected along the subcostal line in the transversus abdominis plane 20 ml 0.25% bupivacaine on each side after aspiration to avoid intravascular placement, and the dissection of the plane was observed. The block was performed bilaterally.
Study NCT06670508 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane block
Description: Group B, the patient was placed in the prone position. Then, the Erector Spinae block was given by same ultrasound transducer . It was sagittaly placed against the target vertebral level (T7 transverse process) in the prone position and moved in approximately 3-cm lateral to the spinous process.. The Erector Spinae muscle and transverse process was identified, and a same blunted tip , 20-gauge, short bevel needle was advanced, using the in-plane approach, in cephalad-to-caudal direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle, as evidenced by visible hydro-dissection below the muscle plane. The block was performed bilaterally by injecting 40 mL of 0.25% bupivacaine (20 mL into each side) into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally.
Study NCT04940286 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT04940286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT04940286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT04940286 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Given IV
Study NCT06622928 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Echocardiographic Assessments:~Pre-Hemodialysis Echocardiography:~Before each hemodialysis session, echocardiograms will be performed to evaluate cardiac function and gather baseline data on ventriculo-arterial coupling (VAC) parameters. This will include recording three apical echocardiographic views (4-chamber, 2-chamber, and 3-chamber) by a trained sonographer.~Post-Hemodialysis Echocardiography:~Following the completion of the hemodialysis session, echocardiographic assessments will be repeated to measure changes in VAC parameters and other relevant cardiac metrics.
Study NCT06684197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intravenous dexmedetomidine will be given as a bolus (0.5 μg.kg-1) over 10 minutes. A perfusion of 0.5 mcg.kg-1.h-1 of dexmedetomidine will be programmed and maintained up until the pneumoperitoneum is deflated or up until a total dose of 2.5μg.kg-1 has been administered.
Study NCT06684197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline will be used instead of dexmedetomidine
Study NCT06214078 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nicotinamide mononucleotide
Description: Nicotinamide mononucleotide (NMN), a bioactive substance found in a variety of foods, is a precursor for the synthesis of nicotinamide adenine dinucleotide (NAD+). NAD+ plays a crucial role in a variety of biological processes including cell death, senescence, gene expression, neuroinflammation, and DNA repair.
Study NCT06214078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo mimicked the appearance and properties of nicotinamide mononucleotide(NMN) enteric-coated capsules. The specifications, usage and dosage of placebo were the same as those of NMN.
Study NCT04745299 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lenzumestrocel
Description: Single cycle administration group : injections twice in a 26-day interval Multiple administration group : injections twice in a 26-day interval followed by repeated three times injections every three months
Study NCT04745299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole
Description: concomitant administration of Riluzole to all groups, except subjects to whom Riluzole administration is deemed impossible owing to adverse events as determined by medical experts
Study NCT04745299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: concomitant administration of Riluzole to all groups, except subjects to whom Riluzole administration is deemed impossible owing to adverse events as determined by medical experts
Study NCT04745299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Single cycle administration group: Placebo comparator is injected three times every three months after injection of Lenzumestrocel twice in a 26-day interval.~Control group: Placebo comparator is injected twice in a 26-day interval followed by repeated three times injcections every three months
Study NCT04745299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: Single cycle administration group: Placebo comparator is injected three times every three months after injection of Lenzumestrocel twice in a 26-day interval.~Control group: Placebo comparator is injected twice in a 26-day interval followed by repeated three times injcections every three months
Study NCT06096519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information, motivation, behavioral skills treatment arm
Description: Our intervention will be an updated version of (Guy2Guy) G2G, a 2014 text messaging-based healthy sexuality and HIV prevention program specifically for 14-18 year old gay, bisexual, and queer (GBQ) adolescent males. The treatment arm of G2G was guided by the Information-Motivation-Behavioral Skills (IMB) model and proved to be efficacious at increasing HIV testing in 13-18 year old GBQ adolescent males. In this updated version we will continue to utilize the IMB model, but modernize the content to include updated HIV prevention information (e.g., novel methods of HIV testing, PrEP, PEP) and tailor the text-message content to meet the needs of adolescent sexual minority men and transgender and gender diverse adolescents.
Study NCT06096519 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Information only control arm
Description: This information only control arm will consist of content and text messages focused on health behavior information, including mood, sexual health, substance use, and other health behaviors. It will be identical in length to the intervention arm.
Study NCT06635148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-81201887
Description: No study intervention will be administered as part of this LTE study.
Study NCT06635148 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: No study intervention will be administered as part of this LTE study.
Study NCT05891548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS-AX
Description: CLS-AX will be administered by suprachoroidal injection into the study eye on Day 1 and then every 12 to 24 weeks as determined by protocol-defined disease activity criteria.
Study NCT05891548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept will be administered by intravitreal injection into the study eye once every 8 weeks (Q8W).
Study NCT06220604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally.
Study NCT06220604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally.
Study NCT06220604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally.
Study NCT06220604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-77242113 Matching Placebo
Description: JNJ-77242113 matching placebo will be administered orally.